Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Clin Cancer Res. 2016 Oct 19;23(9):2154–2158. doi: 10.1158/1078-0432.CCR-16-1948

Figure 2. Survival outcomes for patients treated with ibrutinib-rituximab (IR) – Complex vs Non-Complex karyotype A).

Figure 2

Median PFS in patients with Complex vs Non-Complex karyotype was 31.8 months vs not reached (P=0.76) B) OS according to the presence or absence of complex karyotype; median survival not reached in both group of patients (P=0.67).